Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Practical Considerations in Molecular Testing in CRC

February 26th 2016

Prognostic and Predictive Markers in Colorectal Cancer

February 26th 2016

Salvage Therapy and Emerging Agents in Colorectal Cancer

February 25th 2016

Jennifer Wu, MD, reviews recently approved agents in refractory colorectal cancer, as well as biomarker-directed emerging therapies in the setting.

Dr. Wiesner on Benefits of Genetic Testing in Colorectal Cancer

February 24th 2016

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, explains the benefits of genetic testing for colorectal cancer (CRC) and how oncologists can discuss it with their patients.

Genomic Complexity Stifles Targeted Advances in Colorectal Cancer

February 16th 2016

Experts in the field assert that the path forward requires a paradigm shift toward integrative analyses that encompass multiple classes of genomic aberrations and consensus classification of CRC based on genomic data to facilitate more effective management of this disease.

Sequencing Decisions in Relapsed/Refractory Colorectal Cancer

February 12th 2016

The Role of TAS-102 in Metastatic Colorectal Cancer

February 12th 2016

Regorafenib in Advanced Colorectal Cancer: Dosing Strategies

February 12th 2016

Second-Line Therapy Options in mCRC

February 12th 2016

Considering Maintenance Therapy in mCRC

February 12th 2016

Optimizing Frontline Chemotherapy in mCRC

February 12th 2016

FOLFOX versus FOLFIRI in the MAVERICC Trial in CRC

February 12th 2016

Systemic Therapy Approaches in mCRC

February 12th 2016

Immunotherapy and MSI Status in Colorectal Cancer

February 12th 2016

Molecular Profiling in Colorectal Cancer

February 12th 2016

Liver-Directed Therapies in Metastatic Colorectal Cancer

February 12th 2016

Metastatic Colorectal Cancer: Goals of Resection

February 12th 2016

Taking a Multidisciplinary Approach to mCRC Care

February 12th 2016

Patient Populations Provide Sequencing Clues in Chemorefractory CRC

February 11th 2016

Treating patients with chemorefractory advanced colorectal cancer has undergone a significant transformation in recent years. Now, with two agents approved, the optimal sequence for therapies regorafenib and TAS-102 becomes the next relevant question.

PFS in Metastatic Colorectal Cancer Similar with Two Chemo Backbones

January 26th 2016

A potential biomarker to guide chemotherapy for metastatic colorectal cancer failed to stratify patients by progression-free survival or responsiveness to bevacizumab.